<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02601560</url>
  </required_header>
  <id_info>
    <org_study_id>D5780C00002</org_study_id>
    <nct_id>NCT02601560</nct_id>
  </id_info>
  <brief_title>To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease</brief_title>
  <official_title>A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single- Ascending Doses of MEDI6012 in Subjects With Stable Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2a randomized, double-blind (subject/investigator blinded, MedImmune
      unblinded), placebo-controlled, dose-escalation study to evaluate the safety, PK/PD, and
      immunogenicity of single IV and SC MEDI6012 doses in adult subjects with stable CAD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 3, 2015</start_date>
  <completion_date type="Actual">November 3, 2016</completion_date>
  <primary_completion_date type="Actual">August 20, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)</measure>
    <time_frame>Baseline (Day 1) up to Day 57</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are the events between first dose of study drug and up to 57 days after last dose that were absent before treatment or that worsened relative to pre-treatment state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With TEAEs Related to Electrocardiogram (ECG) Evaluations</measure>
    <time_frame>Baseline (Day 1) up to Day 57</time_frame>
    <description>TEAEs observed in participants with clinically significant ECG abnormalities were assessed. TEAEs are the events between first dose of study drug and up to 57 days after last dose that were absent before treatment or that worsened relative to pre-treatment state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With TEAEs Related to Vital Sign Parameters</measure>
    <time_frame>Baseline (Day 1) up to Day 57</time_frame>
    <description>TEAEs observed in participants with clinically significant vital signs abnormalities were assessed. Vital signs parameters included blood pressure, respiration rate, pulse, pulse oximetry, and body temperature.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With TEAEs Related to Clinical Laboratory Evaluations</measure>
    <time_frame>Baseline (Day 1) up to Day 57</time_frame>
    <description>An abnormal laboratory finding which required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation were reported as an adverse event. Laboratory evaluations (haematology, serum chemistry and urinalysis) of blood and urine samples were performed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hours (Hrs) (AUC [0-96 Hrs]) for High-Density Lipoprotein-Cholesterol (HDL-C)</measure>
    <time_frame>Pre-dose, 12, 24, 48, 72 and 96 hrs post-dose Day 1 for IV and SC dose; additional within 5 minutes after completion of infusion, 4 and 8 hrs post-dose Day 1 (IV cohorts only)</time_frame>
    <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of HDL-C.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for Total Cholesterol</measure>
    <time_frame>Pre-dose, 12, 24, 48, 72 and 96 hrs post-dose Day 1 for IV and SC dose; additional within 5 minutes after completion of infusion and 4 and 8 hrs post-dose Day 1 (IV cohorts only)</time_frame>
    <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of total cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for Free Cholesterol</measure>
    <time_frame>Pre-dose, 12, 24, 48, 72 and 96 hrs post-dose Day 1 for IV and SC dose; additional within 5 minutes after completion of infusion and 4 and 8 hrs post-dose Day 1 (IV cohorts only)</time_frame>
    <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of free cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for Cholesteryl Ester</measure>
    <time_frame>Pre-dose, 12, 24, 48, 72 and 96 hrs post-dose Day 1 for IV and SC dose; additional within 5 minutes after completion of infusion and 4 and 8 hrs post-dose Day 1 (IV cohorts only)</time_frame>
    <description>The AUC(0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of cholesteryl ester.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for High-Density Lipoprotein Cholesteryl Ester</measure>
    <time_frame>Pre-dose, 12, 24, 48, 72 and 96 hrs post-dose Day 1 for IV and SC dose; additional within 5 minutes after completion of infusion and 4 and 8 hrs post-dose Day 1 (IV cohorts only)</time_frame>
    <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of high density lipoprotein cholesteryl ester.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for Non-High Density Lipoprotein Cholesterol</measure>
    <time_frame>Pre-dose, 12, 24, 48, 72 and 96 hrs post-dose Day 1 for IV and SC dose; additional within 5 minutes after completion of infusion and 4 and 8 hrs post-dose Day 1 (IV cohorts only)</time_frame>
    <description>The AUC(0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of non-high density lipoprotein cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for High-Density Lipoprotein Unesterified Cholesterol</measure>
    <time_frame>Pre-dose, 12, 24, 48, 72 and 96 hrs post-dose Day 1 for IV and SC dose; additional within 5 minutes after completion of infusion and 4 and 8 hrs post-dose Day 1 (IV cohorts only)</time_frame>
    <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of high density lipoprotein unesterified cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for Non-High Density Lipoprotein Cholesteryl Ester</measure>
    <time_frame>Pre-dose, 12, 24, 48, 72 and 96 hrs post-dose Day 1 for IV and SC dose; additional within 5 minutes after completion of infusion and 4 and 8 hrs post-dose Day 1 (IV cohorts only)</time_frame>
    <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of non-high density lipoprotein cholesteryl ester.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for Non-High Density Lipoprotein Unesterified Cholesterol</measure>
    <time_frame>Pre-dose, 12, 24, 48, 72 and 96 hrs post-dose Day 1 for IV and SC dose; additional within 5 minutes after completion of infusion and 4 and 8 hrs post-dose Day 1 (IV cohorts only)</time_frame>
    <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of non-high density lipoprotein unesterified cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for Low Density Lipoprotein-Cholesterol (Direct)</measure>
    <time_frame>Pre-dose, 12, 24, 48, 72 and 96 hrs post-dose Day 1 for IV and SC dose; additional within 5 minutes after completion of infusion and 4 and 8 hrs post-dose Day 1 (IV cohorts only)</time_frame>
    <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of low density lipoprotein cholesterol (direct).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) Post Dose for Apolipoprotein B</measure>
    <time_frame>Pre-dose, 12, 24, 48, 72 and 96 hrs post-dose Day 1 for IV and SC dose; additional within 5 minutes after completion of infusion and 4 and 8 hrs post-dose Day 1 (IV cohorts only)</time_frame>
    <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of apolipoprotein B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Concentration of Pre Beta 1-High Density Lipoprotein at Day 29</measure>
    <time_frame>Baseline (Day 1) and Day 29</time_frame>
    <description>The change from baseline in serum concentration of pre beta 1-high density lipoprotein was estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Concentration of Lecithin-Cholesterol Acyltransferase (LCAT) at Day 57</measure>
    <time_frame>Baseline (Day 1) and Day 57</time_frame>
    <description>The change from baseline in serum concentration of lecithin-cholesterol acyltransferase was estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) of MEDI6012</measure>
    <time_frame>Pre-dose and within 5 minutes; 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120 and 168 hrs post-dose Day 1 for IV and SC dose, Day 15 and Day 29; additional 30 min after start of 1-hour infusion (IV cohorts only)</time_frame>
    <description>The first occurrence of the maximum observed plasma concentration of MEDI6012 determined directly from the raw concentration time data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Concentration Maximum (Tmax) of MEDI6012</measure>
    <time_frame>Pre-dose and within 5 minutes; 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120 and 168 hrs post-dose Day 1 for IV and SC dose, Day 15 and Day 29; additional 30 min after start of 1-hour infusion (IV cohorts only)</time_frame>
    <description>The time at which Cmax of MEDI6012 was observed determined directly from raw concentration time data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time Curve From 0 to 168 Hrs (AUC [0-168]) of MEDI6012</measure>
    <time_frame>Pre-dose and within 5 minutes; 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120 and 168 hrs post-dose Day 1 for IV and SC dose, Day 15 and Day 29; additional 30 min after start of 1-hour infusion (IV cohorts only)</time_frame>
    <description>The area under the concentration-time curve from 0 to 168 hrs of MEDI6012.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time Curve From Time Zero to Last Quantifiable Concentration (AUC [0-last]) of MEDI6012</measure>
    <time_frame>Pre-dose and within 5 minutes; 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120 and 168 hrs post-dose Day 1 for IV and SC dose, Day 15 and Day 29; additional 30 min after start of 1-hour infusion (IV cohorts only)</time_frame>
    <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUC [0-last]) of MEDI6012.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time Curve to Infinite Time (AUC [0-inf]) of MEDI6012</measure>
    <time_frame>Pre-dose and within 5 minutes; 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120 and 168 hrs post-dose Day 1 for IV and SC dose, Day 15 and Day 29; additional 30 min after start of 1-hour infusion (IV cohorts only)</time_frame>
    <description>The area under the concentration-time curve to infinite time of MEDI6012.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half Life (t1/2) of MEDI6012</measure>
    <time_frame>Pre-dose and within 5 minutes; 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120 and 168 hrs post-dose Day 1 for IV and SC dose, Day 15 and Day 29; additional 30 min after start of 1-hour infusion (IV cohorts only)</time_frame>
    <description>The t1/2 is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Anti-Drug Antibodies for MEDI6012</measure>
    <time_frame>Day 1 (pre-dose), 15, 29 and 57</time_frame>
    <description>Participants were tested for immunogenicity to MEDI6012. The neutralization assay measures the capacity of participant's plasma (antibodies) to inhibit the binding of MEDI6012 to its target.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>MEDI6012 24 mg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI6012 80 mg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI6012 240 mg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI6012 800 mg IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI6012 80 mg SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single SC dose of 80 mg MEDI6012 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Intravenous (IV)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI6012 600 mg SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Subcutaneous (SC)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI6012</intervention_name>
    <description>Participants received a single IV (24, 80, 240, and 800 mg) and SC (80 and 600 mg) MEDI6012 doses on Day 1.</description>
    <arm_group_label>MEDI6012 24 mg IV</arm_group_label>
    <arm_group_label>MEDI6012 80 mg IV</arm_group_label>
    <arm_group_label>MEDI6012 240 mg IV</arm_group_label>
    <arm_group_label>MEDI6012 800 mg IV</arm_group_label>
    <arm_group_label>MEDI6012 80 mg SC</arm_group_label>
    <arm_group_label>MEDI6012 600 mg SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo SC</intervention_name>
    <description>Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
    <arm_group_label>Placebo Subcutaneous (SC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo IV</intervention_name>
    <description>Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
    <arm_group_label>Placebo Intravenous (IV)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women 40 - 75 years old

          -  History of Stable CAD

          -  Currently receiving statin as standard of care

        Exclusion Criteria:

          -  Severe angina pectoris symptoms

          -  High-risk coronary or carotid artery disease that will likely require surgical or
             percutaneous intervention during the study period

          -  Hospitalization for heart failure within 12 months prior to screening

          -  Uncontrolled Hypertension

          -  Within 6 months prior to screening, a history of ACS or hospitalization for heart
             failure

          -  Clinically significant abnormalities in rhythm, conduction or morphology of ECG

          -  Subjects with transplanted heart, left ventricular assist device, implanted pacemaker,
             implantable cardioverter defibrillator, or cardiac resynchronization therapy

          -  Untreated life-threatening ventricular arrhythmias

          -  History, within 12 months prior to screening, of myocarditis or restrictive
             pericarditis, or hemodynamically significant valvular hear disease or aortic disease

          -  Undergone major surgery with in 3 months prior to screening or has planned major
             surgery during the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2015</study_first_submitted>
  <study_first_submitted_qc>November 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2015</study_first_posted>
  <results_first_submitted>December 8, 2017</results_first_submitted>
  <results_first_submitted_qc>March 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 19, 2018</results_first_posted>
  <disposition_first_submitted>August 1, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>August 16, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 18, 2017</disposition_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>CAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 230 participants were screened in the study from 07-Dec-2015 to 13-Jan-2017 at 8 sites in the United States of America.</recruitment_details>
      <pre_assignment_details>Out of 230 participants, 182 participants were considered screen failures. The remaining 48 participants were randomized to receive the study drug. The 1600 mg dose was omitted based on a greater than expected pharmacodynamics effects at lower doses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Intravenous (IV)</title>
          <description>Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
        </group>
        <group group_id="P2">
          <title>MEDI6012 24 Milligram (mg) IV</title>
          <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>MEDI6012 80 mg IV</title>
          <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>MEDI6012 240 mg IV</title>
          <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>MEDI6012 800 mg IV</title>
          <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
        </group>
        <group group_id="P6">
          <title>Placebo Subcutaneous (SC)</title>
          <description>Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
        </group>
        <group group_id="P7">
          <title>MEDI6012 80 mg SC</title>
          <description>Participants received a single SC dose of 80 mg MEDI6012 on Day 1.</description>
        </group>
        <group group_id="P8">
          <title>MEDI6012 600 mg SC</title>
          <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>As-treated Population: All participants who received any amount of study drug were included in this population.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Intravenous (IV)</title>
          <description>Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
        </group>
        <group group_id="B2">
          <title>MEDI6012 24 Milligram (mg) IV</title>
          <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>MEDI6012 80 mg IV</title>
          <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>MEDI6012 240 mg IV</title>
          <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>MEDI6012 800 mg IV</title>
          <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>Placebo Subcutaneous (SC)</title>
          <description>Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
        </group>
        <group group_id="B7">
          <title>MEDI6012 80 mg SC</title>
          <description>Participants received a single SC dose of 80 mg MEDI6012 on Day 1.</description>
        </group>
        <group group_id="B8">
          <title>MEDI6012 600 mg SC</title>
          <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="4"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.8" spread="6.5"/>
                    <measurement group_id="B2" value="59.8" spread="7.0"/>
                    <measurement group_id="B3" value="60.0" spread="6.4"/>
                    <measurement group_id="B4" value="63.5" spread="5.4"/>
                    <measurement group_id="B5" value="65.8" spread="8.2"/>
                    <measurement group_id="B6" value="62.0" spread="9.3"/>
                    <measurement group_id="B7" value="71.3" spread="3.4"/>
                    <measurement group_id="B8" value="66.5" spread="4.7"/>
                    <measurement group_id="B9" value="64.0" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are the events between first dose of study drug and up to 57 days after last dose that were absent before treatment or that worsened relative to pre-treatment state.</description>
        <time_frame>Baseline (Day 1) up to Day 57</time_frame>
        <population>As-treated Population: All participants who received any amount of study drug were included in this population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Intravenous (IV)</title>
            <description>Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>MEDI6012 24 Milligram (mg) IV</title>
            <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI6012 80 mg IV</title>
            <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI6012 240 mg IV</title>
            <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI6012 800 mg IV</title>
            <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Subcutaneous (SC)</title>
            <description>Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O7">
            <title>MEDI6012 80 mg SC</title>
            <description>Participants received a single SC dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>MEDI6012 600 mg SC</title>
            <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are the events between first dose of study drug and up to 57 days after last dose that were absent before treatment or that worsened relative to pre-treatment state.</description>
          <population>As-treated Population: All participants who received any amount of study drug were included in this population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TESAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With TEAEs Related to Electrocardiogram (ECG) Evaluations</title>
        <description>TEAEs observed in participants with clinically significant ECG abnormalities were assessed. TEAEs are the events between first dose of study drug and up to 57 days after last dose that were absent before treatment or that worsened relative to pre-treatment state.</description>
        <time_frame>Baseline (Day 1) up to Day 57</time_frame>
        <population>As-treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Intravenous (IV)</title>
            <description>Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>MEDI6012 24 Milligram (mg) IV</title>
            <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI6012 80 mg IV</title>
            <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI6012 240 mg IV</title>
            <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI6012 800 mg IV</title>
            <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Subcutaneous (SC)</title>
            <description>Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O7">
            <title>MEDI6012 80 mg SC</title>
            <description>Participants received a single SC dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>MEDI6012 600 mg SC</title>
            <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs Related to Electrocardiogram (ECG) Evaluations</title>
          <description>TEAEs observed in participants with clinically significant ECG abnormalities were assessed. TEAEs are the events between first dose of study drug and up to 57 days after last dose that were absent before treatment or that worsened relative to pre-treatment state.</description>
          <population>As-treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With TEAEs Related to Vital Sign Parameters</title>
        <description>TEAEs observed in participants with clinically significant vital signs abnormalities were assessed. Vital signs parameters included blood pressure, respiration rate, pulse, pulse oximetry, and body temperature.</description>
        <time_frame>Baseline (Day 1) up to Day 57</time_frame>
        <population>As-treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Intravenous (IV)</title>
            <description>Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>MEDI6012 24 Milligram (mg) IV</title>
            <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI6012 80 mg IV</title>
            <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI6012 240 mg IV</title>
            <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI6012 800 mg IV</title>
            <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Subcutaneous (SC)</title>
            <description>Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O7">
            <title>MEDI6012 80 mg SC</title>
            <description>Participants received a single SC dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>MEDI6012 600 mg SC</title>
            <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs Related to Vital Sign Parameters</title>
          <description>TEAEs observed in participants with clinically significant vital signs abnormalities were assessed. Vital signs parameters included blood pressure, respiration rate, pulse, pulse oximetry, and body temperature.</description>
          <population>As-treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With TEAEs Related to Clinical Laboratory Evaluations</title>
        <description>An abnormal laboratory finding which required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation were reported as an adverse event. Laboratory evaluations (haematology, serum chemistry and urinalysis) of blood and urine samples were performed.</description>
        <time_frame>Baseline (Day 1) up to Day 57</time_frame>
        <population>As-treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Intravenous (IV)</title>
            <description>Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>MEDI6012 24 Milligram (mg) IV</title>
            <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI6012 80 mg IV</title>
            <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI6012 240 mg IV</title>
            <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI6012 800 mg IV</title>
            <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Subcutaneous (SC)</title>
            <description>Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O7">
            <title>MEDI6012 80 mg SC</title>
            <description>Participants received a single SC dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>MEDI6012 600 mg SC</title>
            <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs Related to Clinical Laboratory Evaluations</title>
          <description>An abnormal laboratory finding which required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation were reported as an adverse event. Laboratory evaluations (haematology, serum chemistry and urinalysis) of blood and urine samples were performed.</description>
          <population>As-treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hours (Hrs) (AUC [0-96 Hrs]) for High-Density Lipoprotein-Cholesterol (HDL-C)</title>
        <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of HDL-C.</description>
        <time_frame>Pre-dose, 12, 24, 48, 72 and 96 hrs post-dose Day 1 for IV and SC dose; additional within 5 minutes after completion of infusion, 4 and 8 hrs post-dose Day 1 (IV cohorts only)</time_frame>
        <population>As-treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Intravenous (IV)</title>
            <description>Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>MEDI6012 24 Milligram (mg) IV</title>
            <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI6012 80 mg IV</title>
            <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI6012 240 mg IV</title>
            <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI6012 800 mg IV</title>
            <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Subcutaneous (SC)</title>
            <description>Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O7">
            <title>MEDI6012 80 mg SC</title>
            <description>Participants received a single SC dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>MEDI6012 600 mg SC</title>
            <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hours (Hrs) (AUC [0-96 Hrs]) for High-Density Lipoprotein-Cholesterol (HDL-C)</title>
          <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of HDL-C.</description>
          <population>As-treated Population.</population>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.1" spread="120.0"/>
                    <measurement group_id="O2" value="728.3" spread="334.2"/>
                    <measurement group_id="O3" value="1639.9" spread="631.7"/>
                    <measurement group_id="O4" value="3035.0" spread="439.1"/>
                    <measurement group_id="O5" value="5318.3" spread="1674.3"/>
                    <measurement group_id="O6" value="-113.5" spread="289.4"/>
                    <measurement group_id="O7" value="422.4" spread="395.7"/>
                    <measurement group_id="O8" value="2844.7" spread="1219.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.095</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.440</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for Total Cholesterol</title>
        <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of total cholesterol.</description>
        <time_frame>Pre-dose, 12, 24, 48, 72 and 96 hrs post-dose Day 1 for IV and SC dose; additional within 5 minutes after completion of infusion and 4 and 8 hrs post-dose Day 1 (IV cohorts only)</time_frame>
        <population>As-treated population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Intravenous (IV)</title>
            <description>Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>MEDI6012 24 Milligram (mg) IV</title>
            <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI6012 80 mg IV</title>
            <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI6012 240 mg IV</title>
            <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI6012 800 mg IV</title>
            <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Subcutaneous (SC)</title>
            <description>Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O7">
            <title>MEDI6012 80 mg SC</title>
            <description>Participants received a single SC dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>MEDI6012 600 mg SC</title>
            <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for Total Cholesterol</title>
          <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of total cholesterol.</description>
          <population>As-treated population</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="954.1"/>
                    <measurement group_id="O2" value="-164.9" spread="1301.5"/>
                    <measurement group_id="O3" value="1925.7" spread="913.3"/>
                    <measurement group_id="O4" value="3639.2" spread="667.6"/>
                    <measurement group_id="O5" value="6990.3" spread="1764.0"/>
                    <measurement group_id="O6" value="82.3" spread="983.4"/>
                    <measurement group_id="O7" value="240.9" spread="494.2"/>
                    <measurement group_id="O8" value="3156.8" spread="1476.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for Free Cholesterol</title>
        <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of free cholesterol.</description>
        <time_frame>Pre-dose, 12, 24, 48, 72 and 96 hrs post-dose Day 1 for IV and SC dose; additional within 5 minutes after completion of infusion and 4 and 8 hrs post-dose Day 1 (IV cohorts only)</time_frame>
        <population>As-treated population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Intravenous (IV)</title>
            <description>Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>MEDI6012 24 Milligram (mg) IV</title>
            <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI6012 80 mg IV</title>
            <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI6012 240 mg IV</title>
            <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI6012 800 mg IV</title>
            <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Subcutaneous (SC)</title>
            <description>Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O7">
            <title>MEDI6012 80 mg SC</title>
            <description>Participants received a single SC dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>MEDI6012 600 mg SC</title>
            <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for Free Cholesterol</title>
          <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of free cholesterol.</description>
          <population>As-treated population</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.4" spread="265.4"/>
                    <measurement group_id="O2" value="-197.7" spread="338.2"/>
                    <measurement group_id="O3" value="38.9" spread="346.8"/>
                    <measurement group_id="O4" value="110.0" spread="133.9"/>
                    <measurement group_id="O5" value="434.6" spread="541.7"/>
                    <measurement group_id="O6" value="172.5" spread="76.6"/>
                    <measurement group_id="O7" value="-61.5" spread="206.6"/>
                    <measurement group_id="O8" value="-205.4" spread="324.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for Cholesteryl Ester</title>
        <description>The AUC(0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of cholesteryl ester.</description>
        <time_frame>Pre-dose, 12, 24, 48, 72 and 96 hrs post-dose Day 1 for IV and SC dose; additional within 5 minutes after completion of infusion and 4 and 8 hrs post-dose Day 1 (IV cohorts only)</time_frame>
        <population>As-treated population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Intravenous (IV)</title>
            <description>Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>MEDI6012 24 Milligram (mg) IV</title>
            <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI6012 80 mg IV</title>
            <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI6012 240 mg IV</title>
            <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI6012 800 mg IV</title>
            <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Subcutaneous (SC)</title>
            <description>Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O7">
            <title>MEDI6012 80 mg SC</title>
            <description>Participants received a single SC dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>MEDI6012 600 mg SC</title>
            <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for Cholesteryl Ester</title>
          <description>The AUC(0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of cholesteryl ester.</description>
          <population>As-treated population</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.6" spread="776.0"/>
                    <measurement group_id="O2" value="32.8" spread="992.6"/>
                    <measurement group_id="O3" value="1886.8" spread="722.8"/>
                    <measurement group_id="O4" value="3529.2" spread="628.3"/>
                    <measurement group_id="O5" value="6555.7" spread="1674.0"/>
                    <measurement group_id="O6" value="-90.2" spread="965.4"/>
                    <measurement group_id="O7" value="302.4" spread="428.4"/>
                    <measurement group_id="O8" value="3362.3" spread="1340.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for High-Density Lipoprotein Cholesteryl Ester</title>
        <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of high density lipoprotein cholesteryl ester.</description>
        <time_frame>Pre-dose, 12, 24, 48, 72 and 96 hrs post-dose Day 1 for IV and SC dose; additional within 5 minutes after completion of infusion and 4 and 8 hrs post-dose Day 1 (IV cohorts only)</time_frame>
        <population>As-treated population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Intravenous (IV)</title>
            <description>Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>MEDI6012 24 Milligram (mg) IV</title>
            <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI6012 80 mg IV</title>
            <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI6012 240 mg IV</title>
            <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI6012 800 mg IV</title>
            <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Subcutaneous (SC)</title>
            <description>Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O7">
            <title>MEDI6012 80 mg SC</title>
            <description>Participants received a single SC dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>MEDI6012 600 mg SC</title>
            <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for High-Density Lipoprotein Cholesteryl Ester</title>
          <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of high density lipoprotein cholesteryl ester.</description>
          <population>As-treated population</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.3" spread="108.9"/>
                    <measurement group_id="O2" value="668.4" spread="263.3"/>
                    <measurement group_id="O3" value="1460.7" spread="584.0"/>
                    <measurement group_id="O4" value="2778.0" spread="416.7"/>
                    <measurement group_id="O5" value="4886.0" spread="1459.7"/>
                    <measurement group_id="O6" value="-132.6" spread="253.1"/>
                    <measurement group_id="O7" value="392.7" spread="350.3"/>
                    <measurement group_id="O8" value="2672.5" spread="1115.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for Non-High Density Lipoprotein Cholesterol</title>
        <description>The AUC(0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of non-high density lipoprotein cholesterol.</description>
        <time_frame>Pre-dose, 12, 24, 48, 72 and 96 hrs post-dose Day 1 for IV and SC dose; additional within 5 minutes after completion of infusion and 4 and 8 hrs post-dose Day 1 (IV cohorts only)</time_frame>
        <population>As-treated population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Intravenous (IV)</title>
            <description>Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>MEDI6012 24 Milligram (mg) IV</title>
            <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI6012 80 mg IV</title>
            <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI6012 240 mg IV</title>
            <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI6012 800 mg IV</title>
            <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Subcutaneous (SC)</title>
            <description>Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O7">
            <title>MEDI6012 80 mg SC</title>
            <description>Participants received a single SC dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>MEDI6012 600 mg SC</title>
            <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for Non-High Density Lipoprotein Cholesterol</title>
          <description>The AUC(0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of non-high density lipoprotein cholesterol.</description>
          <population>As-treated population</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.0" spread="906.4"/>
                    <measurement group_id="O2" value="-893.2" spread="1316.0"/>
                    <measurement group_id="O3" value="285.8" spread="1051.8"/>
                    <measurement group_id="O4" value="604.2" spread="659.1"/>
                    <measurement group_id="O5" value="1672.0" spread="1413.4"/>
                    <measurement group_id="O6" value="195.8" spread="809.9"/>
                    <measurement group_id="O7" value="-181.5" spread="385.1"/>
                    <measurement group_id="O8" value="312.2" spread="642.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for High-Density Lipoprotein Unesterified Cholesterol</title>
        <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of high density lipoprotein unesterified cholesterol.</description>
        <time_frame>Pre-dose, 12, 24, 48, 72 and 96 hrs post-dose Day 1 for IV and SC dose; additional within 5 minutes after completion of infusion and 4 and 8 hrs post-dose Day 1 (IV cohorts only)</time_frame>
        <population>As-treated population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Intravenous (IV)</title>
            <description>Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>MEDI6012 24 Milligram (mg) IV</title>
            <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI6012 80 mg IV</title>
            <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI6012 240 mg IV</title>
            <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI6012 800 mg IV</title>
            <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Subcutaneous (SC)</title>
            <description>Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O7">
            <title>MEDI6012 80 mg SC</title>
            <description>Participants received a single SC dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>MEDI6012 600 mg SC</title>
            <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for High-Density Lipoprotein Unesterified Cholesterol</title>
          <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of high density lipoprotein unesterified cholesterol.</description>
          <population>As-treated population</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="38.0"/>
                    <measurement group_id="O2" value="59.9" spread="78.9"/>
                    <measurement group_id="O3" value="179.2" spread="116.5"/>
                    <measurement group_id="O4" value="248.4" spread="37.6"/>
                    <measurement group_id="O5" value="417.1" spread="256.1"/>
                    <measurement group_id="O6" value="19.1" spread="46.6"/>
                    <measurement group_id="O7" value="29.7" spread="77.5"/>
                    <measurement group_id="O8" value="172.2" spread="156.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for Non-High Density Lipoprotein Cholesteryl Ester</title>
        <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of non-high density lipoprotein cholesteryl ester.</description>
        <time_frame>Pre-dose, 12, 24, 48, 72 and 96 hrs post-dose Day 1 for IV and SC dose; additional within 5 minutes after completion of infusion and 4 and 8 hrs post-dose Day 1 (IV cohorts only)</time_frame>
        <population>As-treated population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Intravenous (IV)</title>
            <description>Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>MEDI6012 24 Milligram (mg) IV</title>
            <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI6012 80 mg IV</title>
            <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI6012 240 mg IV</title>
            <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI6012 800 mg IV</title>
            <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Subcutaneous (SC)</title>
            <description>Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O7">
            <title>MEDI6012 80 mg SC</title>
            <description>Participants received a single SC dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>MEDI6012 600 mg SC</title>
            <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for Non-High Density Lipoprotein Cholesteryl Ester</title>
          <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of non-high density lipoprotein cholesteryl ester.</description>
          <population>As-treated population</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8" spread="748.1"/>
                    <measurement group_id="O2" value="-635.6" spread="984.0"/>
                    <measurement group_id="O3" value="426.1" spread="723.0"/>
                    <measurement group_id="O4" value="741.6" spread="590.5"/>
                    <measurement group_id="O5" value="1649.5" spread="1007.5"/>
                    <measurement group_id="O6" value="42.4" spread="791.6"/>
                    <measurement group_id="O7" value="-90.3" spread="390.6"/>
                    <measurement group_id="O8" value="689.8" spread="634.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for Non-High Density Lipoprotein Unesterified Cholesterol</title>
        <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of non-high density lipoprotein unesterified cholesterol.</description>
        <time_frame>Pre-dose, 12, 24, 48, 72 and 96 hrs post-dose Day 1 for IV and SC dose; additional within 5 minutes after completion of infusion and 4 and 8 hrs post-dose Day 1 (IV cohorts only)</time_frame>
        <population>As-treated population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Intravenous (IV)</title>
            <description>Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>MEDI6012 24 Milligram (mg) IV</title>
            <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI6012 80 mg IV</title>
            <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI6012 240 mg IV</title>
            <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI6012 800 mg IV</title>
            <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Subcutaneous (SC)</title>
            <description>Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O7">
            <title>MEDI6012 80 mg SC</title>
            <description>Participants received a single SC dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>MEDI6012 600 mg SC</title>
            <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for Non-High Density Lipoprotein Unesterified Cholesterol</title>
          <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of non-high density lipoprotein unesterified cholesterol.</description>
          <population>As-treated population</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.2" spread="241.2"/>
                    <measurement group_id="O2" value="-257.6" spread="351.8"/>
                    <measurement group_id="O3" value="-140.3" spread="354.7"/>
                    <measurement group_id="O4" value="-132.2" spread="139.9"/>
                    <measurement group_id="O5" value="27.8" spread="609.9"/>
                    <measurement group_id="O6" value="153.4" spread="72.9"/>
                    <measurement group_id="O7" value="-91.2" spread="155.2"/>
                    <measurement group_id="O8" value="-377.6" spread="280.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for Low Density Lipoprotein-Cholesterol (Direct)</title>
        <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of low density lipoprotein cholesterol (direct).</description>
        <time_frame>Pre-dose, 12, 24, 48, 72 and 96 hrs post-dose Day 1 for IV and SC dose; additional within 5 minutes after completion of infusion and 4 and 8 hrs post-dose Day 1 (IV cohorts only)</time_frame>
        <population>As-treated population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Intravenous (IV)</title>
            <description>Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>MEDI6012 24 Milligram (mg) IV</title>
            <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI6012 80 mg IV</title>
            <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI6012 240 mg IV</title>
            <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI6012 800 mg IV</title>
            <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Subcutaneous (SC)</title>
            <description>Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O7">
            <title>MEDI6012 80 mg SC</title>
            <description>Participants received a single SC dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>MEDI6012 600 mg SC</title>
            <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) for Low Density Lipoprotein-Cholesterol (Direct)</title>
          <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of low density lipoprotein cholesterol (direct).</description>
          <population>As-treated population</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182.1" spread="600.9"/>
                    <measurement group_id="O2" value="-473.0" spread="1096.4"/>
                    <measurement group_id="O3" value="83.2" spread="762.0"/>
                    <measurement group_id="O4" value="987.2" spread="453.8"/>
                    <measurement group_id="O5" value="1812.8" spread="1081.8"/>
                    <measurement group_id="O6" value="-101.6" spread="854.2"/>
                    <measurement group_id="O7" value="-61.7" spread="438.1"/>
                    <measurement group_id="O8" value="996.1" spread="803.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) Post Dose for Apolipoprotein B</title>
        <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of apolipoprotein B.</description>
        <time_frame>Pre-dose, 12, 24, 48, 72 and 96 hrs post-dose Day 1 for IV and SC dose; additional within 5 minutes after completion of infusion and 4 and 8 hrs post-dose Day 1 (IV cohorts only)</time_frame>
        <population>As-treated population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Intravenous (IV)</title>
            <description>Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>MEDI6012 24 Milligram (mg) IV</title>
            <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI6012 80 mg IV</title>
            <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI6012 240 mg IV</title>
            <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI6012 800 mg IV</title>
            <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Subcutaneous (SC)</title>
            <description>Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O7">
            <title>MEDI6012 80 mg SC</title>
            <description>Participants received a single SC dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>MEDI6012 600 mg SC</title>
            <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline-adjusted Area Under the Curve From Time 0 to 96 Hrs (AUC [0-96 Hrs]) Post Dose for Apolipoprotein B</title>
          <description>The AUC (0-96 hrs) is the area under the concentration-time curve from time 0 to 96 hrs of apolipoprotein B.</description>
          <population>As-treated population</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220.7" spread="524.7"/>
                    <measurement group_id="O2" value="-795.5" spread="695.5"/>
                    <measurement group_id="O3" value="-636.7" spread="682.6"/>
                    <measurement group_id="O4" value="-649.5" spread="208.6"/>
                    <measurement group_id="O5" value="-537.1" spread="706.2"/>
                    <measurement group_id="O6" value="97.4" spread="483.2"/>
                    <measurement group_id="O7" value="-309.0" spread="270.5"/>
                    <measurement group_id="O8" value="-219.0" spread="630.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Concentration of Pre Beta 1-High Density Lipoprotein at Day 29</title>
        <description>The change from baseline in serum concentration of pre beta 1-high density lipoprotein was estimated.</description>
        <time_frame>Baseline (Day 1) and Day 29</time_frame>
        <population>As-treated population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Intravenous (IV)</title>
            <description>Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>MEDI6012 24 Milligram (mg) IV</title>
            <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI6012 80 mg IV</title>
            <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI6012 240 mg IV</title>
            <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI6012 800 mg IV</title>
            <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Subcutaneous (SC)</title>
            <description>Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O7">
            <title>MEDI6012 80 mg SC</title>
            <description>Participants received a single SC dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>MEDI6012 600 mg SC</title>
            <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Concentration of Pre Beta 1-High Density Lipoprotein at Day 29</title>
          <description>The change from baseline in serum concentration of pre beta 1-high density lipoprotein was estimated.</description>
          <population>As-treated population.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68" spread="2.24"/>
                    <measurement group_id="O2" value="1.75" spread="0.37"/>
                    <measurement group_id="O3" value="2.08" spread="1.19"/>
                    <measurement group_id="O4" value="2.53" spread="1.80"/>
                    <measurement group_id="O5" value="4.85" spread="4.01"/>
                    <measurement group_id="O6" value="3.90">Standard deviation cannot be determined as only 1 participant was available.</measurement>
                    <measurement group_id="O7" value="3.38" spread="1.48"/>
                    <measurement group_id="O8" value="1.67" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="1.27"/>
                    <measurement group_id="O2" value="-0.02" spread="0.84"/>
                    <measurement group_id="O3" value="0.13" spread="0.32"/>
                    <measurement group_id="O4" value="0.40" spread="0.62"/>
                    <measurement group_id="O5" value="-1.12" spread="3.21"/>
                    <measurement group_id="O6" value="-1.10">Standard deviation cannot be determined as only 1 participant was available.</measurement>
                    <measurement group_id="O7" value="1.33" spread="1.44"/>
                    <measurement group_id="O8" value="0.10" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Concentration of Lecithin-Cholesterol Acyltransferase (LCAT) at Day 57</title>
        <description>The change from baseline in serum concentration of lecithin-cholesterol acyltransferase was estimated.</description>
        <time_frame>Baseline (Day 1) and Day 57</time_frame>
        <population>Pharmacokinetic (PK) population: All participants in the as-treated population who had atleast one detectable LCAT serum concentration measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI6012 24 Milligram (mg) IV</title>
            <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI6012 80 mg IV</title>
            <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI6012 240 mg IV</title>
            <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI6012 800 mg IV</title>
            <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI6012 80 mg SC</title>
            <description>Participants received a single SC dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI6012 600 mg SC</title>
            <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Concentration of Lecithin-Cholesterol Acyltransferase (LCAT) at Day 57</title>
          <description>The change from baseline in serum concentration of lecithin-cholesterol acyltransferase was estimated.</description>
          <population>Pharmacokinetic (PK) population: All participants in the as-treated population who had atleast one detectable LCAT serum concentration measurement.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1250.0" spread="0.0"/>
                    <measurement group_id="O2" value="1250.0" spread="0.0"/>
                    <measurement group_id="O3" value="1250.0" spread="0.0"/>
                    <measurement group_id="O4" value="1250.0" spread="0.0"/>
                    <measurement group_id="O5" value="1250.0" spread="0.0"/>
                    <measurement group_id="O6" value="1250.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0">Standard deviation cannot be determined as only 1 participant was available.</measurement>
                    <measurement group_id="O4" value="0.0" spread="0.0"/>
                    <measurement group_id="O5" value="0.0">Standard deviation cannot be determined as only 1 participant was available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Serum Concentration (Cmax) of MEDI6012</title>
        <description>The first occurrence of the maximum observed plasma concentration of MEDI6012 determined directly from the raw concentration time data.</description>
        <time_frame>Pre-dose and within 5 minutes; 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120 and 168 hrs post-dose Day 1 for IV and SC dose, Day 15 and Day 29; additional 30 min after start of 1-hour infusion (IV cohorts only)</time_frame>
        <population>PK population. PK data of MEDI6012 80 mg SC dose group was not interpretable as concentration levels were predominantly beneath the limit of quantitation (&lt;2.5 mcg/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI6012 24 Milligram (mg) IV</title>
            <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI6012 80 mg IV</title>
            <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI6012 240 mg IV</title>
            <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI6012 800 mg IV</title>
            <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI6012 600 mg SC</title>
            <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Serum Concentration (Cmax) of MEDI6012</title>
          <description>The first occurrence of the maximum observed plasma concentration of MEDI6012 determined directly from the raw concentration time data.</description>
          <population>PK population. PK data of MEDI6012 80 mg SC dose group was not interpretable as concentration levels were predominantly beneath the limit of quantitation (&lt;2.5 mcg/mL).</population>
          <units>micrograms/milliliter (mcg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.02" spread="2.25"/>
                    <measurement group_id="O2" value="20.2" spread="4.15"/>
                    <measurement group_id="O3" value="73.5" spread="9.40"/>
                    <measurement group_id="O4" value="229" spread="55.4"/>
                    <measurement group_id="O5" value="22.8" spread="9.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Concentration Maximum (Tmax) of MEDI6012</title>
        <description>The time at which Cmax of MEDI6012 was observed determined directly from raw concentration time data.</description>
        <time_frame>Pre-dose and within 5 minutes; 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120 and 168 hrs post-dose Day 1 for IV and SC dose, Day 15 and Day 29; additional 30 min after start of 1-hour infusion (IV cohorts only)</time_frame>
        <population>PK population. PK data of MEDI6012 80 mg SC dose group was not interpretable as concentration levels were predominantly beneath the limit of quantitation (&lt;2.5 mcg/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI6012 24 Milligram (mg) IV</title>
            <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI6012 80 mg IV</title>
            <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI6012 240 mg IV</title>
            <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI6012 800 mg IV</title>
            <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI6012 600 mg SC</title>
            <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Concentration Maximum (Tmax) of MEDI6012</title>
          <description>The time at which Cmax of MEDI6012 was observed determined directly from raw concentration time data.</description>
          <population>PK population. PK data of MEDI6012 80 mg SC dose group was not interpretable as concentration levels were predominantly beneath the limit of quantitation (&lt;2.5 mcg/mL).</population>
          <units>hrs</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="2.25" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.00" spread="4.15" lower_limit="1.00" upper_limit="1.50"/>
                    <measurement group_id="O3" value="1.00" spread="9.40" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O4" value="1.00" spread="55.4" lower_limit="1.00" upper_limit="1.50"/>
                    <measurement group_id="O5" value="48.0" spread="9.75" lower_limit="48.0" upper_limit="72.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Time Curve From 0 to 168 Hrs (AUC [0-168]) of MEDI6012</title>
        <description>The area under the concentration-time curve from 0 to 168 hrs of MEDI6012.</description>
        <time_frame>Pre-dose and within 5 minutes; 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120 and 168 hrs post-dose Day 1 for IV and SC dose, Day 15 and Day 29; additional 30 min after start of 1-hour infusion (IV cohorts only)</time_frame>
        <population>PK population. PK data of MEDI6012 80 mg SC dose group was not interpretable as concentration levels were predominantly beneath the limit of quantitation (&lt;2.5 mcg/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI6012 24 Milligram (mg) IV</title>
            <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI6012 80 mg IV</title>
            <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI6012 240 mg IV</title>
            <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI6012 800 mg IV</title>
            <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI6012 600 mg SC</title>
            <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time Curve From 0 to 168 Hrs (AUC [0-168]) of MEDI6012</title>
          <description>The area under the concentration-time curve from 0 to 168 hrs of MEDI6012.</description>
          <population>PK population. PK data of MEDI6012 80 mg SC dose group was not interpretable as concentration levels were predominantly beneath the limit of quantitation (&lt;2.5 mcg/mL).</population>
          <units>mcg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137" spread="55.0"/>
                    <measurement group_id="O2" value="805" spread="265"/>
                    <measurement group_id="O3" value="2760" spread="249"/>
                    <measurement group_id="O4" value="8470" spread="2000"/>
                    <measurement group_id="O5" value="2460" spread="824"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Time Curve From Time Zero to Last Quantifiable Concentration (AUC [0-last]) of MEDI6012</title>
        <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUC [0-last]) of MEDI6012.</description>
        <time_frame>Pre-dose and within 5 minutes; 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120 and 168 hrs post-dose Day 1 for IV and SC dose, Day 15 and Day 29; additional 30 min after start of 1-hour infusion (IV cohorts only)</time_frame>
        <population>PK population. PK data of MEDI6012 80 mg SC dose group was not interpretable as concentration levels were predominantly beneath the limit of quantitation (&lt;2.5 mcg/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI6012 24 Milligram (mg) IV</title>
            <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI6012 80 mg IV</title>
            <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI6012 240 mg IV</title>
            <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI6012 800 mg IV</title>
            <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI6012 600 mg SC</title>
            <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time Curve From Time Zero to Last Quantifiable Concentration (AUC [0-last]) of MEDI6012</title>
          <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUC [0-last]) of MEDI6012.</description>
          <population>PK population. PK data of MEDI6012 80 mg SC dose group was not interpretable as concentration levels were predominantly beneath the limit of quantitation (&lt;2.5 mcg/mL).</population>
          <units>mcg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.8" spread="42.7" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="683" spread="267" lower_limit="1.00" upper_limit="1.50"/>
                    <measurement group_id="O3" value="2760" spread="249" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O4" value="9020" spread="2760" lower_limit="1.00" upper_limit="1.50"/>
                    <measurement group_id="O5" value="2460" spread="824" lower_limit="48.0" upper_limit="72.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Time Curve to Infinite Time (AUC [0-inf]) of MEDI6012</title>
        <description>The area under the concentration-time curve to infinite time of MEDI6012.</description>
        <time_frame>Pre-dose and within 5 minutes; 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120 and 168 hrs post-dose Day 1 for IV and SC dose, Day 15 and Day 29; additional 30 min after start of 1-hour infusion (IV cohorts only)</time_frame>
        <population>PK population. PK data of MEDI6012 80 mg SC dose group was not interpretable as concentration levels were predominantly beneath the limit of quantitation (&lt;2.5 mcg/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI6012 24 Milligram (mg) IV</title>
            <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI6012 80 mg IV</title>
            <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI6012 240 mg IV</title>
            <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI6012 800 mg IV</title>
            <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI6012 600 mg SC</title>
            <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time Curve to Infinite Time (AUC [0-inf]) of MEDI6012</title>
          <description>The area under the concentration-time curve to infinite time of MEDI6012.</description>
          <population>PK population. PK data of MEDI6012 80 mg SC dose group was not interpretable as concentration levels were predominantly beneath the limit of quantitation (&lt;2.5 mcg/mL).</population>
          <units>mcg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137" spread="56.1"/>
                    <measurement group_id="O2" value="887" spread="308"/>
                    <measurement group_id="O3" value="3030" spread="298"/>
                    <measurement group_id="O4" value="9510" spread="2720"/>
                    <measurement group_id="O5" value="3560" spread="732"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Half Life (t1/2) of MEDI6012</title>
        <description>The t1/2 is the time measured for the plasma concentration to decrease by one half.</description>
        <time_frame>Pre-dose and within 5 minutes; 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120 and 168 hrs post-dose Day 1 for IV and SC dose, Day 15 and Day 29; additional 30 min after start of 1-hour infusion (IV cohorts only)</time_frame>
        <population>PK population. PK data of MEDI6012 80 mg SC dose group was not interpretable as concentration levels were predominantly beneath the limit of quantitation (&lt;2.5 mcg/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI6012 24 Milligram (mg) IV</title>
            <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI6012 80 mg IV</title>
            <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI6012 240 mg IV</title>
            <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI6012 800 mg IV</title>
            <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI6012 600 mg SC</title>
            <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Half Life (t1/2) of MEDI6012</title>
          <description>The t1/2 is the time measured for the plasma concentration to decrease by one half.</description>
          <population>PK population. PK data of MEDI6012 80 mg SC dose group was not interpretable as concentration levels were predominantly beneath the limit of quantitation (&lt;2.5 mcg/mL).</population>
          <units>hrs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" spread="5.47"/>
                    <measurement group_id="O2" value="46.9" spread="17.6"/>
                    <measurement group_id="O3" value="45.7" spread="3.67"/>
                    <measurement group_id="O4" value="55.4" spread="14.2"/>
                    <measurement group_id="O5" value="89.5" spread="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Positive Anti-Drug Antibodies for MEDI6012</title>
        <description>Participants were tested for immunogenicity to MEDI6012. The neutralization assay measures the capacity of participant's plasma (antibodies) to inhibit the binding of MEDI6012 to its target.</description>
        <time_frame>Day 1 (pre-dose), 15, 29 and 57</time_frame>
        <population>Immunogenicity population: All participants in the as-treated population with at least one serum sample available for immunogenicity testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Intravenous (IV)</title>
            <description>Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O2">
            <title>MEDI6012 24 Milligram (mg) IV</title>
            <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI6012 80 mg IV</title>
            <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI6012 240 mg IV</title>
            <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI6012 800 mg IV</title>
            <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Subcutaneous (SC)</title>
            <description>Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
          </group>
          <group group_id="O7">
            <title>MEDI6012 80 mg SC</title>
            <description>Participants received a single SC dose of 80 mg MEDI6012 on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>MEDI6012 600 mg SC</title>
            <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Anti-Drug Antibodies for MEDI6012</title>
          <description>Participants were tested for immunogenicity to MEDI6012. The neutralization assay measures the capacity of participant's plasma (antibodies) to inhibit the binding of MEDI6012 to its target.</description>
          <population>Immunogenicity population: All participants in the as-treated population with at least one serum sample available for immunogenicity testing.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (predose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from baseline (Day 1) throughout the treatment period and including the follow-up period (up to Day 57).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Intravenous (IV)</title>
          <description>Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
        </group>
        <group group_id="E2">
          <title>MEDI6012 24 Milligram (mg) IV</title>
          <description>Participants received a single IV dose of 24 mg MEDI6012 on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>MEDI6012 80 mg IV</title>
          <description>Participants received a single IV dose of 80 mg MEDI6012 on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>MEDI6012 240 mg IV</title>
          <description>Participants received a single IV dose of 240 mg MEDI6012 on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>MEDI6012 800 mg IV</title>
          <description>Participants received a single IV dose of 800 mg MEDI6012 on Day 1.</description>
        </group>
        <group group_id="E6">
          <title>Placebo Subcutaneous (SC)</title>
          <description>Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.</description>
        </group>
        <group group_id="E7">
          <title>MEDI6012 80 mg SC</title>
          <description>Participants received a single SC dose of 80 mg MEDI6012 on Day 1.</description>
        </group>
        <group group_id="E8">
          <title>MEDI6012 600 mg SC</title>
          <description>Participants received a single SC dose of 600 mg MEDI6012 on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infusion site bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infusion site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Medical device site irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>High density lipoprotein decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Respiratory rate increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Slow speech</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Microalbuminuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard George, MD, Director, Clinical Development</name_or_title>
      <organization>MedImmune, LLC</organization>
      <phone>+1-301-398-5681</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

